This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Caristo Diagnostics Limited has announced the results of a landmark clinical study published in The Lancet that support the ability of Caristo's CaRi-Heart AI technology to quantify coronaryartery inflammation and accurately predict cardiac events. fold higher risk for cardiac mortality and 5.5-fold
Food and Drug Administration ( FDA ) approval for the AGENT Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronaryarterydisease. vs. 3.9%, P=0.001), a 49% risk reduction in heartattack at the target vessel (6.4% vs. 28.7%; P=0.006).
milla1cf Wed, 03/06/2024 - 18:48 March 6, 2024 — Cleerly , the company on a mission to create a new standard of care to aid in the diagnosis of heartdisease, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration ( FDA ) for its CoronaryArteryDisease ( CAD ) Staging System.
These technologies are not just reshaping but also empowering how cardiology practices manage operations, deliver care, and enhance patient outcomes. These technologies are reshaping how cardiology practices manage operations, deliver care, and enhance patient outcomes.
A therapy that has been proven repeatedly to reduce the probability of heartattacks and strokes in multiple double-blind randomised controlled studies 1. They are also at an increased risk of coronaryarterydisease (Discussed in more detail here ). This one requires some nuance. 2022 Sep 10;400(10355):832-845.
Together, the two companies will work to further the development and commercialization of Medis Quantitative Flow Ratio (Medis QFR), a non-invasive approach to the assessment of coronary physiology, as part of GE HealthCare’s interventional cardiology portfolio built around the Allia Platform.
a provider of AI technology for coronaryarterydisease (CAD) management, recently introduced its new brand identity reflecting its focus on delivering clarity, precision and confidence in the prevention, diagnosisand treatment of CAD. References Centers for Disease Control and Prevention. HeartDisease Facts.
Cleerly is dedicated to creating a new standard of care for heartdisease by using FDA-cleared solutions powered by artificial intelligence. We are very excited to see our purpose-driven mission come to life, making advanced cardiac care accessible to more patients and working towards our goal of eliminating heartattacks.” “We
Food and Drug Administration (FDA) 510(k) clearance of its CaRi-Plaquetechnology, an AI-assisted image analysis application to aid the diagnosis of coronaryarterydisease (CAD). For decades, heartdisease has been treated reactively, waiting for symptoms to appear before taking action.
Genes influence various biological processes, including cholesterol metabolism, blood pressure regulation, and the strength and structure of your heart and blood vessels. A family history of heartdisease often indicates that genetic factors might be at play. How Do Genetic Factors Work?
Improved patient safety with reduced radiation and contrast load Enhancing patient safety is a pivotal aspect of advanced cardiac imaging technology. By employing advanced scanning technology, healthcare providers can ensure patients undergo diagnostic procedures with minimized risks.
mg tablets), together with Caristo Diagnostics , a leading cardiac disease diagnostics company with the novel CaRi-Hearttechnology to visualize and quantify coronary inflammation, announced today their collaboration to improve awareness and clinical education about the central role of inflammation in coronaryarterydisease.
With the addition of Shockwave, Johnson & Johnson will expand its MedTech cardiovascular portfolio into two of the highest-growth, innovation-oriented segments of cardiovascular intervention – coronaryarterydisease (CAD) and peripheral arterydisease (PAD).
milla1cf Wed, 03/13/2024 - 16:52 March 13, 2024 — In the largest randomized clinical trial and first of its kind to date in the United States, a team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) assessed the efficacy and safety of using a drug-coated balloon in patients undergoing coronary angioplasty. and Susan F.
CT coronary angiography, in addition to a CT CAC, is arguably the best test for estimating whether someone has evidence of coronaryarterydisease and what that means for their near-term risk of a heartattack. This article is part 2 of a series on cardiac CT. The dark grey is the Non Calcified plaque.
The machine prints out a graph containing information about the heart's activity. This visual information is used by a healthcare professional to analyze heart health. Technological advancements have revolutionized the medical industry; now, portable ECG devices are also available. ECG tests can also show previous heartattacks.
Technology provides us with more and more possibilities in many areas of life, including medicine. It is no longer just a future dream, but a new reality for clinicians and patients who can already benefit from new technologies. Cardiovascular diseases are a group of diseases of the heart and blood vessels.
a provider of non-invasive artificial intelligence (AI) heart care solutions, and Boone Heart Institute , a Denver area provider of preventive cardiovascular care, has launched the GAMEFILM Registry, a post-market, data collection registry designed to define cardiac risk in retired National Football League (NFL) players.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content